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Human TRAV1-2-negative MR1-restricted
T cells detect S. pyogenes and alternatives
to MAIT riboﬂavin-based antigens
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Mucosal-associated invariant T (MAIT) cells are thought to detect microbial antigens
presented by the HLA-Ib molecule MR1 through the exclusive use of a TRAV1-2-containing
TCRa. Here we use MR1 tetramer staining and ex vivo analysis with mycobacteria-infected
MR1-deﬁcient cells to demonstrate the presence of functional human MR1-restricted T cells
that lack TRAV1-2. We characterize an MR1-restricted clone that expresses the TRAV12-2
TCRa, which lacks residues previously shown to be critical for MR1-antigen recognition. In
contrast to TRAV1-2þ MAITcells, this TRAV12-2-expressing clone displays a distinct pattern
of microbial recognition by detecting infection with the riboﬂavin auxotroph Streptococcus
pyogenes. As known MAITantigens are derived from riboﬂavin metabolites, this suggests that
TRAV12-2þ clone recognizes unique antigens. Thus, MR1-restricted T cells can discriminate
between microbes in a TCR-dependent manner. We postulate that additional MR1-restricted
T-cell subsets may play a unique role in defence against infection by broadening the
recognition of microbial metabolites.
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H
uman mucosal-associated invariant T (MAIT) cells have
been described as an abundant population of ab-T-cell
antigen receptor (TCR) T cells that display antimicrobial
Th1-like cytotoxic capacity upon detection of a range of microbial
infections1–3. By deﬁnition, MAIT cells express a semi-invariant
TCR that engages antigenic ligands presented by the HLA-Ib
major histocompatibility complex (MHC)-related protein I
(MR1). MR1 has been shown to present small compounds
derived from folic acid and riboﬂavin biosynthesis, the latter of
which can activate MAIT cells4–6. In healthy humans, MAIT cells
account for 1–10% of T cells in peripheral blood. They are also
abundant in the liver and in a number of mucosal tissues1,7–11.
Thymic selection and peripheral expansion of MAIT cells depend
on MR1 (refs 11,12). Furthermore, MAIT cells with effector
function have been found in the thymus, a ﬁnding that has been
used to support their deﬁnition as innate-like13. While the role of
MR1 and MAIT cells in human immunity is unclear, mouse
studies have demonstrated their role in protection against
bacterial infections including Klebsiella pneumoniae,
Mycobacterium bovis Bacillus Calmette–Gue´rin (BCG) and
Francisella tularensis live vaccine strain (LVS)14–16.
MR1 is an HLA-Ib MHC class I molecule thought to be highly
conserved in mammalian evolution17. MR1 can bind vitamin
B-based precursors derived from folic acid (vitamin B9) and
riboﬂavin (vitamin B2) biosynthesis that share a common pterin
ring structure5. So far, only those from the riboﬂavin synthetic
pathway have been shown to stimulate MAIT cells. These
stimulating ligands can be derived from either pyrimidine-based
early intermediates in riboﬂavin synthesis (5-A-RU) that form
adducts with other small metabolites (for example, 5-OP-RU) or
the direct lumazine precursors of riboﬂavin (for example,
ribityllumazine (RL)-6,7-diMe)4,5. Because riboﬂavin synthesis
does not occur in humans, riboﬂavin metabolites presented in the
context of MR1 have been suggested to be pathogen-associated
molecular patterns. However, evidence supports the existence of
additional MR1 ligands. For example, structural analysis suggests
that plasticity in the MR1-binding groove could accommodate a
range of different ligands4,18–22. As the pterin ring occurs
commonly in the environment, it is feasible that other microbial
or host molecules with common chemotypic properties could
bind to MR1 and function as antigens for MR1-restricted T cells.
Although MAIT cells speciﬁcally recognize infection by
pathogens with the capacity to synthesize riboﬂavin1,3, whether
microbe-speciﬁc MR1 ligands exist is unknown. We previously
evaluated the ex vivo human TCR repertoire of MAIT cells
responsive to three riboﬂavin-synthesizing microbes23, ﬁnding
that distinct MAIT TCR usage was associated with microbe-
selective responses within and across individuals. These data
support the hypothesis that MR1 can present discrete microbial
ligands, and that this presentation is in turn associated with
selective clonal expansion of MAIT cells. However, it is not
known whether each microbe synthesizes the same repertoire of
riboﬂavin metabolites, but at varying proportions, or whether
there are unique ligands.
The nature of the diversity in MR1 ligand repertoire suggests an
accordingly diverse MAIT TCR repertoire to mediate ligand
recognition. Human MAIT TCRa chains have been described as
being invariant, comprising TRAV1-2/TRAJ12, 20, 33 genes paired
with a limited array of TCR b-chains1,11,13,24,25. However, other
studies have identiﬁed greater TCR heterogeneity through more
diverse TCRa and TCRb chain usage10,23,26–28. Gherardin et al.28
described TRAV1-2-negative TCRs that bind selectively to MR1
tetramers loaded with 5-OP-RU (riboﬂavin metabolite), or
6FP/acetyl-6FP (folate derivative), or both. These TRAV1-2-
negative TCRs represent unprecedented diverse TRAV and
TRBV usage by MR1-restricted T cells. These ﬁndings suggest
that MR1-restricted T cells could use diverse TCRs to recognize
microbial infection; therefore, the full repertoire of TCRs that can
be used by MR1-restricted T cells is unknown.
Here we describe microbe-reactive MR1-restricted T cells that
do not express TRAV1-2. Functional analysis reveals that these
cells, although less prevalent than those that express TRAV1-2,
can be found in PBMC from all individuals. Among MR1-Ag
tetramer-positive cells, 1–4% are TRAV1-2-negative. T-cell
cloning conﬁrms the usage of an alternative TCRa chain,
TRAV12-2, by an MR1-restricted T-cell clone from one donor.
In comparison with previously described TRAV1-2þ MAIT cells,
this T-cell clone displays a unique pattern of ligand and microbial
selectivity. Most notably, the TRAV12-2 T-cell clone could detect
infection with Streptococcus pyogenes in a TCR-dependent
manner, a microbe that is not capable of synthesizing riboﬂavin.
These data, then, provide direct evidence of the ability of MR1 to
present a diverse array of ligands, which in turn is associated with
selective TCR usage. Finally, our ﬁndings challenge the current
paradigm of sole usage of TRAV1-2 in conjunction with the
recognition of riboﬂavin metabolites being the deﬁning feature of
MR1-restricted T cells.
Results
Enumeration of functional TRAV1-2 MR1-restricted T cells.
MAIT cells can detect a wide range of bacteria and fungi through
recognition of riboﬂavin metabolites presented by the HLA-Ib
molecule MR1. In this context, we sought to explore the relative
contribution of MR1 to the entire HLA-Ib-restricted CD8þ
T-cell response to microbial infection. In order to quantify and
characterize these responses directly ex vivo, we have developed a
functional ex vivo assay that relies upon cytokine production by
CD8þ T cells in response to microbial infection of HLA-mis-
matched A549 cells1. The ﬂow cytometry gating scheme used to
analyse this response is shown in Supplementary Fig. 1. Using
this approach, we have consistently been able to enumerate MAIT
cells (TRAV1-2þ ) responsive to a number of microbes such as
Mtb1,13,23, Candida albicans and Salmonella typhimurium
infections23. However, we also consistently observed TRAV1-2-
negative cells reactive to these same microbes. For example,
nearly 50% of the CD8þ HLA-Ib response to M. smegmatis
(M. smegmatis) was TRAV1-2-negative in a representative donor,
D462 (Fig. 1).
To address the hypothesis that TRAV1-2-negative cells were
MR1-restricted, we generated an MR1-knockout A549 cell line29.
Brieﬂy, CRISPR/Cas9 technology was used to generate a single
base pair deletion and a 125-bp deletion separately on each allele
to ablate expression of MR1. To conﬁrm the absence of MR1 in a
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Figure 1 | M. smegmatis infection elicits a response from MAIT cells and
TRAV1-2 HLA-Ib-restricted CD8þ T cells. PBMC-derived CD8þ T cells
from adult donor (D462) were stimulated ex vivo by A549 cells infected
with M. smegmatis to identify mycobacteria-reactive HLA-Ib T cells.
Functional MAITcells were identiﬁed by production of IFN-g and expression
of TRAV1-2 TCR. Numbers in quadrants indicate the % of live CD3þ cells.
Experiments were performed three independent times with similar results.
Representative results are shown.
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functional assay, the wild-type (WT) and MR1 / cell lines
were infected with mycobacteria and T-cell responses evaluated
by interferon (IFN)-g ELISPOT. As shown in Fig. 2a, activation
of the TRAV1-2þ MR1-restricted clone (D426-B1 (ref. 23))
was ablated, while activation of the HLA-E-restricted clone
(D160-1-23) was unaffected, indicating that lack of MR1 did not
affect infectivity or a separate antigen-presentation pathway.
To establish the prevalence of MR1-restricted T-cell responses
ex vivo, WT and MR1 / A549 cells were infected with
M. smegmatis and used as stimulators for CD8þ T cells isolated
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Figure 2 | MR1-restricted microbial-reactive CD8þ T cells from blood do not exclusively express TRAV1-2. (a) IFN-g production by T-cell clones
D160-1-23 (restricted by HLA-E) and D426-B1 (restricted by MR1) in response to mycobacteria-infected WT and MR1 / A549 cell line. (b) Positively
selected CD8þ T cells from PBMC were tested for ex vivo IFN-g responses to M. smegmatis-infected WTor MR1 / A549 cell line. Events are gated on
live CD3þCD4 cells. IFN-g and TRAV1-2 expressions are shown on the x and y axes, respectively. To the right is a summary of the TRAV1-2-negative
response from each donor across experiments. (c) Frequency of IFN-gþ CD4 cells from each donor (represented by one dot) when stimulated by
M. smegmatis-infected WT or MR1 \ A549s, n¼ 5 biological replicates, with n¼ 3 technical replicates. Statistical signiﬁcance of difference between
groups was determined using the nonparametric Mann–Whitney U-test. Error bars are the s.e.m. of triplicates in a,b. Experiments in this ﬁgure were
performed at least twice with similar results. Representative results are shown. *P value40.05 was considered signiﬁcant.
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from PBMC of ﬁve healthy individuals (Fig. 2b). Intracellular IFN-g
production was assessed using ﬂow cytometry. As expected,
TRAV1-2þ cells produced IFN-g in response to M. smegmatis-
infected WT A549 cells. Furthermore, the majority of the response
was MR1-dependent (mean 85.21% MR1-restricted, range
45.3–97.22, n¼ 5, tested in duplicate). Each donor also had a
proportion of TRAV1-2-negative cells whose production of IFN-g
was MR1-dependent (mean 25.83% MR1-restricted, range 10–41.03,
n¼ 5, tested in duplicate; Fig. 2b). The average of the cytokine
responses by the TRAV1-2-negative population for each donor
across experiments was plotted in Fig. 2b (right panel). In order to
conﬁrm the presence of TRAV1-2-negative M. smegmatis-reactive T
cells, we repeated this assay using PBMC that were ﬂuorescence-
activated cell sorting (FACS)-selected on CD8 but depleted of
TRAV1-2þ cells. Then, we stimulated the T cells with WT
(MR1-positive) infected A549 cells. From all donors we observed a
detectable IFN-g-producing population. Therefore, we conclude that
not all microbe-reactive MR1-restricted T cells are TRAV1-2þ .
Cloning TRAV1-2-negative MR1-restricted T cells. To further
characterize TRAV1-2-negative MR1-restricted CD8þ T cells in
each of the ﬁve donors, we used M. smegmatis-infected
antigen-presenting cell (APC) to generate CD8þ TRAV1-2-
negative T-cell lines that were both reactive to M. smegmatis and
whose activation was blocked by the addition of MR1 antibody.
Subsequent cloning of the T-cell line from one donor, D462,
using a-CD3 stimulation was used to establish the T-cell clone,
D462-E4. As shown in Fig. 3a, D462-E4 was characterized by the
uniform expression of CD8a and the absence of TRAV1-2. In
comparison with TRAV1-2þ MAIT cell clones, D462-E4
expressed equivalent levels of TCR and co-stimulatory receptors
(Fig. 3b). This T-cell clone also expressed CD26 (ref. 30) but did
not express CD161 (ref. 7), although CD161 may have been
downregulated as the result of expansion with anti-CD3
(refs 30,31; Fig. 3b). TCR sequence analysis of D462-E4
demonstrated the unique expression of TRAV12-2/TRAJ39 TCRa
and TRBV29-1/TRBJ1-5 TCRb (Fig. 3c and Supplementary
Table 1). The expression of the TCRb chain was conﬁrmed by
antibody staining, which showed staining on D462-E4 but not
by MAIT T-cell clone, D481-A9, that expresses TRBV20-11. We
conﬁrmed that the clone was M. smegmatis-reactive using
infected epithelial cells, and restricted with MR1 using antibody
blockade (Fig. 3d). The D462-E4 clone retained the ability to
recognize M. smegmatis-infected cells in a manner that was
blocked by a-MR1, but not by the pan-HLA I antibody W6/32,
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Figure 3 | Isolation of an MR1-restricted T-cell clone that reacts to bacteria independently of the TRAV1-2 TCR. Generation of a CD8þ T-cell line and
then T-cell clone, D462-E4, through FACS sorting on CD8þ , gd TCR , TRAV1-2-negative T cells from donor in (Fig. 1) and co-culturing for 7 days with
M. smegmatis-infected autologous DCs. The line was stained with CFSE and co-cultured for 7 days with M. smegmatis-infected autologous macrophages.
(a) Staining of TRAV1-2 and co-receptor CD8 on T-cell clone D462-E4. (b) Comparison of T-cell surface marker expression on TRAV1-2-negative clone D462-E4
(black) and TRAV1-2þ MAITclone D426-G11 (grey) and (c) of TRBV 29-1 on D462-E4 and D481-A9 TRAV1-2þ MAITclone. TCR ab CDR3 sequences and gene
names of D462-E4 are shown, right. (d) BEAS2B cell line infected with mycobacteria and tested for their ability to stimulate T-cell clones in the presence of blocking
antibodies or isotype by IFN-g ELISPOT assays, D462-E4, D481-F12 (TRAV1-2þ MAIT) and D466-A10 (HLA-B45). (e) Flow cytometry of clones with MR1
tetramer loaded with 6-formyl pterin (grey) or 5-OP-RU (clear). D462-E4, D481-A9 MAIT clone and D466-A10 HLA-B45-restricted T-cell clone. Error bars
represent the s.e.m. of triplicates. Experiments were performed at least two times with similar results. Representative results are shown.
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nor by any of the CD1-blocking antibodies. These results are
similar to the pattern seen by the known MR1-restricted T-cell
clones (D481-F12, Fig. 3d). The clonality and MR1 reactivity of
D462-E4 was conﬁrmed by staining with the MR1-Ag tetramer
loaded with the MAIT-activating ligand, 5-OP-RU (Fig. 3e).
Notably, clone D462-E4 bound the MR1-Ag tetramer with the
same level of intensity as the TRAV1-2þ MAIT cell clone D426-
B1 (ref. 1), while the HLA-B45-restricted clone D466-D6 (ref. 32)
did not bind the tetramer. In contrast, neither MR1-restricted
clone bound the MR1 tetramer loaded with the MAIT cell
inhibitor, 6-formyl pterin (6FP). Collectively, isolation of clone
D462-E4 conﬁrms the presence of microbe-reactive
MR1-restricted CD8þ T cells that detect infection using an
atypical MAIT TCR TRAV12-2.
Differential antigen recognition by MR1-restricted T cells.
Because we had isolated D462-E4 from an M. smegmatis-reactive
T-cell line, we wanted to compare the M. smegmatis reactivity of
TRAV1-2þ and TRAV12-2þ T-cell clones over a range of MOI.
In Fig. 4a, we tested clone D426-G11 and D462-E4 in an IFNg
ELISPOT for their reactivity to infected dendritic cells (DCs).
Although both clones recognized the infection, our data show a
higher potency of antigen dose in regards to the TRAV1-2þ
clone (D426-G11), while both clones displayed similar maximal
efﬁcacy (cytokine release). This result suggested that the
TRAV12-2 TCR either had lower TCR avidity or could recognize
fewer MR1 ligands from the infected cell. Given prior evidence of
MR1 ligand discrimination1,4,20,23,28, we tested whether the
TRAV12-2 TCR had different ligand selectivity in comparison
with the TRAV1-2 MAIT TCR. To deﬁne the MR1 ligands
recognized by the TRAV12-2þ TCR, we ﬁrst tested D462-E4 for
its ability to recognize the A549 cell line loaded with MAIT RL
antigens RL-6,7-diMe and RL-6-Me-7-OH (ref. 5) in the presence
or absence of MR1 blockade. As shown in Fig. 4b, D462-E4
detected both antigens in an MR1-dependent manner. However,
D462-E4 was preferentially stimulated by RL-6-Me-7-OH. In
contrast, two previously characterized MR1-restricted clones
D481-F12 and D426-G11 (refs 1,23) were preferentially
stimulated by the RL-6,7-diMe antigen. To better understand
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Numbers on the overlay indicate the geometric mean ﬂuorescence intensity of at least 30,000 clones. (f) DCs were infected with S. pyogenes at MOI¼ 3,
blocked with anti-MR1 or isotype control (10 mgml 1) and then co-incubated with D462-E4 T-cell clone. IFN-g production was quantiﬁed by ELISPOT.
(g) DCs were either blocked with 6-formyl pterin (50mgml 1) or 0.01M NaOH vehicle control or nothing, and then loaded with S. pyogenes or M.smeg
supernatant (15ml) or PHA at 10mgml 1. The DCs were then used to stimulate T-cell clone D462-E4 and IFN-g production was quantiﬁed by ELISPOT.
Error bars represent the s.e.m. of at least duplicates. Assays were performed three times, with similar results. Representative results are shown.
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whether this differential response was due to TCR avidity, T-cell
activation was tested over a range of antigen concentrations. We
found that the differential responses by D462-E4 compared with
the other MR1-restricted T-cell clones were maintained over a
wide range of concentrations (Fig. 4c). In these experiments, we
observed similar antigen potency (antigen concentration of half
maximum response) yet different maximal efﬁcacy (cytokine
release) in response to the two-RL antigens between the three
MR1-restricted T-cell clones. These responses may be indicative
of different levels of antigen cross-reactivity between these TCRs.
Therefore, we concluded that D462-E4 displayed ligand
discrimination between MAIT RL antigens.
Differential recognition of microbes by MR1-restricted T cells.
To establish the repertoire of microbes recognized by D462-E4, a
diverse array of microbes was tested. DCs and epithelial cells were
infected with microbes at optimized MOI and used to compare
the ability of T-cell clones D462-E4 (TRAV12-2) and D426-G11
(TRAV1-2) to recognize these targets (Fig. 4d). We observed four
patterns of responses from the MAIT T-cell clones: (1) microbes
recognized equivalently by both T-cell clones (M. smegmatis, E.
coli, Yersinia enterolitica and Shigella ﬂexneri), (2) microbes
preferentially recognized by the TRAV1-2þ T-cell clone (M.
avium, S. typhimurium, C. albicans, Nocardia asteroides and
Vibrio parahemolytica), (3) microbes only detected by the
TRAV1-2þ T-cell clone (M. tuberculosis, Staphylococcus aureus,
Pseudomonas aeruginosa and Neisseria gonorrhoeae) and (4)
microbes only recognized by TRAV12-2þ T-cell clone
(S. pyogenes; Fig. 4d). Neither clone responded to the riboﬂavin
auxotroph Enterococcus faecalis. Thus, the TRAV1-2þ MAIT
clone, D426-G11, only responded to microbes with the capacity
to produce riboﬂavin. While the D462-E4 clone was also able to
recognize many of these microbes (Fig. 4d), it was distinguishable
in its ability to respond to infection with S. pyogenes.
S. pyogenes is a bacterium that does not express riboﬂavin
synthesis Rib enzymes33–35 ribA, ribB, ribD, ribH and ribE
(E. coli operon nomenclature). Initially, we conﬁrmed that
S. pyogenes was auxotrophic for this vitamin (Fig. 5a). To
demonstrate the selectivity of the TRAV12-2 T-cell clone for
S. pyogenes, clones were tested over a broad range of MOIs. The
TRAV12-2þ T-cell clone responded over a range of S. pyogenes
MOI in DCs (Fig. 5b), while the TRAV1-2þ clone did not
respond to this infection. To exclude a nonspeciﬁc effect on the
TRAV12-2 clone, cells were incubated with S. pyogenes or ﬁltered
culture supernatant without an APC. Here no activation was
observed (Fig. 5c). In order to establish whether the T-cell clone
was activated by soluble factors from the APC, we used two
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Figure 6 | MR1-Ag tetramerþ CD8þ T cells from peripheral blood do not exclusively express TRAV1-2. PBMCs were stained with antibodies to CD3,
CD4, CD8, TRAV1-2, CD26, CD161, viability stain and human MR1-Ag (5-OP-RU) tetramer. All plots are gated on live, CD3þ , CD4-negative cells. The x axis
represents CD161 expression, and the y axis represents MR1 tetramer (top row), TRAV1-2 (middle row) and CD26 (bottom row). MR1 tetramerþ cells were gated
as indicated by the gate in the top row. MR1 tetramerþ cells were subgated based on TRAV1-2 expression where TRAV1-2-negative events and their frequencies
are shown in red. The second and third rows of plots are overlays of TRAV1-2þ in black and TRAV1-2-negative in red. (b) PBMCs were depleted of
TRAV1-2þ cells by FACS and then stained with MR1-Ag tetramer and T-cell lineage markers (red bars). The black bars and red-patterned bars indicate frequencies
presented in (a) for comparison. This experiment was performed once and (a) was performed twice with similar results. Representative results are shown.
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approaches. First, we tested whether conditioned media from
DCs pulsed with S. pyogenes culture supernatant could activate
D462-E4. Here no activation was observed (Fig. 5c). Second, we
tested whether pulsed ﬁxed DCs would maintain the same pattern
of eliciting T-cell clone activation as unﬁxed pulsed DCs (Fig. 5c).
In this experiment, DCs that had been pulsed with S. pyogenes
supernatant overnight and then ﬁxed were still able to activate
T-cell clone D462-E4, suggesting that the response depends upon
antigen presentation and not soluble factors. We next sought to
determine whether the response to S. pyogenes was dependent
upon the TCR. As shown in Fig. 5d the response to S. pyogenes
could be blocked using the pan ab-TCR non-activating
antibody but not an isotype control. Furthermore, increased
phosphorylation of CD3z the TCR–CD3 complex (the primary
intracellular signal-transducing subunit36) was observed in
D462-E4 following incubation with DCs infected with
M. smegmatis or S. pyogenes (Fig. 5e). ZAP-70 is a tyrosine
kinase that, upon TCR stimulation, is recruited to the TCR–CD3
complex by phosphorylation of the ITAMs of CD3z (ref. 37).
After TCR engagement, the tyrosine residues Y315 and Y319 of
ZAP-70 are phosphorylated. In order to provide further evidence
of TCR stimulation upon recognition of bacterially infected DCs,
we also compared the level of ZAP-70 pY319 between treatments.
Here we also observed increased phosphorylation of this key
residue of ZAP-70 in D462-E4 following incubation with DCs
(Fig. 5e). To determine whether the recognition of S. pyogenes
was dependent on MR1, two approaches were employed. First, we
tested whether the clone’s response to S. pyogenes could be
blocked with antibody to MR1 (Fig. 5f). Here recognition
was efﬁciently inhibited by addition of anti-MR1 but not
isotype control. Second, we employed the MR1 antagonist, 6FP
(Fig. 5g). The response to S. pyogenes, but not mitogen
Phytohaemagglutinin (PHA), was also blocked by addition of
6FP over the vehicle control. Thus, clone D462-E4 detects both
RLs MAIT antigens and an unidentiﬁed streptococcal-derived
antigen in an MR1 and TCR-dependent manner. This unique
detection pattern of infection and ligand recognition by TRAV12-
2þ D462-E4 compared with TRAV1-2þ MAIT cells indicates a
greater diversity in microbial MR1 ligands.
Tetramer staining of TRAV1-2 MR1-restricted T cells. To
establish the prevalence of TRAV1-2-negative MR1-restricted T
cells across healthy individuals, we ﬁrst stained PBMC with the
MR1-Ag (5-OP-RU) tetramer, followed by sequential staining
with antibodies to MAIT-associated surface markers
(Supplementary Fig. 2). As human MAIT cells have been deﬁned
as either CD8þ or CD8CD4 T cells1,24, we quantiﬁed
tetramer staining within the CD4-negative population.
Frequencies of MR1-Ag tetramerþ cells ranged from 0.98 to
4.30% (mean 2.30%, n¼ 5) of the CD4-negative lymphocytes
(Fig. 6, top row). In line with previously published data10, the
majority of MR1-Ag tetramerþ cells expressed the TRAV1-2
TCR (Fig. 6, second row). However, on average, 2.57% of MR1-
Ag tetramerþ cells did not express TRAV1-2 (red events in
Fig. 6). Furthermore, these were present in all donors and ranged
in frequency from 1.40 to 4.22% of tetramerþ cells. TRAV1-2þ
MAIT cells have been phenotypically characterized as cells with
high expression of CD161 (refs 26,38) and CD26 (refs 7,30). In
line with this, the majority of the TRAV1-2þ MR1-Ag
tetramerþ cells co-expressed CD26 and CD161 (mean 96.2%,
s.d. 2.5%; Fig. 6, bottom row). In contrast, a smaller proportion of
tetramerþ TRAV1-2-negative cells expressed CD161 and CD26,
although there was considerable heterogeneity between donors
(mean 60.1%, s.d. 21.6%, range 37.8–86.2%). To exclude the
possibility that tetramer binding masked the staining of TRAV1-
2, we depleted the TRAV1-2þ cells using FACS in three of the
above donors, and then stained the remaining TRAV1-2-negative
cells with the MR1 tetramer. In this case, the estimated TRAV1-2-
negative tetramer frequencies were nearly identical to those seen
before TRAV1-2 depletion (Fig. 6, bottom). This experiment
veriﬁed the frequencies of TRAV1-2-MR1-restricted T cells from
each donor. In sum, these data conﬁrm the presence of T cells
capable of interacting with MR1-Ag that do not express the
TRAV1-2 TCRa in healthy human blood.
Finally, in order to test the generalizability of the antigenic
reactivity observed by clone D462-E4, we generated CD8þ
TRAV1-2-negative MR1 tetramerþ T-cell lines from the four
additional donors used in Fig. 6. Importantly, these T-cell lines
were enriched to 84–97% TRAV1-2-negative of MR1 tetramerþ
cells. We observed equivalent MR1-restricted IFN-g reactivity to
M. smegmatis and S. pyogenes infection by each T-cell line. Taken
together, the conﬁrmation of our ﬁnding from four additional
PBMC donors clearly supports generalized reactivity of TRAV1-
2-negative MR1-restricted T cells across individuals.
Discussion
While MAIT cells have been deﬁned through their usage of the
TRAV1-2 TCR, in this report we demonstrate unambiguously the
presence of MR1-restricted T cells that are TRAV1-2-negative,
demonstrate the speciﬁc usage of the TRAV12-2 TCR by a clone
and ﬁnd that these cells are capable of recognizing both the
previously demonstrated RL riboﬂavin intermediates, as well as
unique ligands derived from S. pyogenes, a bacterium incapable of
riboﬂavin biosynthesis. As a result, our study demonstrates
considerable promiscuity in MR1-restricted T cells, at the level of
the ability of their TCR to recognize antigens, and in the ability of
MR1 to present these ligands.
Here we ﬁnd that TRAV12-2 MR1-restricted T cells can be
stained with the MR1-Ag tetramer, and have the ability to
recognize both known RL antigens as well as an antigen derived
from S. pyogenes. The observation that the TRAV1-2 MR1-
restricted T cell cannot recognize this bacterium provides
deﬁnitive evidence that the antigen being recognized is distinct.
These data, then, would suggest a model in which the MAIT cell
TCR confers selectivity, but not stringent speciﬁcity. Similarly,
our data support the hypothesis that MR1 is capable of presenting
an array of ligands. The observation that MR1-restricted T cells of
varying TCR usage and antigenic selectivity can be broadly
deﬁned by staining with the MR1-Ag (5-OP-RU) tetramer is
reminiscent of CD1d-restricted T cells deﬁned by staining with
the aGalCer tetramer39–41. In these initial studies, human NKT
cells were enumerated using CD1d-aGalCer tetramers and found
to stain with anti-Va24 TCR antibody. More recently,
populations of NKT cells expressing alternative semi-invariant
TCRs that bind to aGalCer-loaded CD1d tetramers have been
identiﬁed42,43. Elucidation of the crystal structure of one of these
alternative TCRs to aGalCer-loaded tetramer showed a similar
binding mode to that of the Va24Ja18 TCR44. Taken together,
this shared phenomenon between MR1 and CD1d antigen
presentation must be what allows selective activation within the
conﬁnes of microbial pattern recognition by unconventional T
cells.
The use of TRAV12-2 TCR by MR1-restricted T cells
necessarily challenges the existing paradigm of how the MAIT
cell TCR interacts with MR1. Prior studies have deﬁned the
structural and functional requirements of the semi-invariant
TRAV1-2 TCR for MAIT cell activation in the context of MR1
and bound ligand4,18–21. These studies deﬁne a clear role for the
CDR3a and possibly the CDR3b loop in ligand recognition.
Speciﬁcally, these studies suggested a conservation of the key
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patterns of TCR residues in the TCR a-chain including the
conserved amino acid, Tyra95 (refs 18–22,45). The critical
tyrosine at position 95 in the CDR3 of the TCRa chain allows for
the formation of a hydrogen bond with MAIT activating but not
non-activating ligands. For example, MR1 binding of the RL-6-
Me-7-OH ligand (that is recognized by D462-E4) allows for a
single TRAV1-2þ TCR contact with TRAV1-2: Tyr95 of the
CDR3a loop20. While this residue is highly conserved between
MAIT TCRs25,46, sequence analysis of TRAV12-2þ D462-E4
demonstrates that this clone lacks a tyrosine residue in its CDR3a
region. We note that we have previously reported that a
proportion of microbial-reactive, TRAV1-2-expressing MR1-
restricted T cells do not contain the Tyra95 (ref. 23). A recent
study by Gherardin et al.28 observed that a TRAV1-2-negative
MR1-restricted TCR (TRAV36/TRAJ34) could instead use an
asparagine residue of its CDR1a to contact the 5-OP-RU-
activating ligand. This elegant study highlights that alternative
molecular interactions can mediate atypical TCR recognition of
MR1-Ag. At present, we cannot comment on the critical residues
that mediate the D462-E4 TCR interaction with MR1 ligand.
Our data clearly support the hypothesis that MR1 can present a
diverse array of ligands to MR1-restricted T cells. First, by
comparing microbial recognition of the TRAV1-2 and TRAV12-2
TCR we have deﬁned patterns of recognition that would imply
the presence of more than one activating ligand. For instance, the
ability of TRAV1-2-expressing T cells to uniquely recognize a
microbe would suggest the presence of a ligand not recognized by
TRAV12-2 TCR. Similarly, those microbes that are preferentially
recognized by the TRAV1-2 T cells likely contain either a single
ligand that is recognized preferentially (analogous to our ﬁndings
of ligand discrimination between RLs in Fig. 4b), or containing
multiple ligands. Most striking, however, was the ability of the
TRAV12-2þ MR1-restricted T cell to recognize S. pyogenes, an
organism that cannot synthesize riboﬂavin. Because this pathogen
is not recognized by the TRAV1-2þ T cells, these data would
unambiguously refute the hypothesis that differential MAIT cell
recognition can be simply explained by differing proportions of
riboﬂavin metabolites. At present, the MR1 ligand from S.
pyogenes remains to be determined. Recent molecular analyses
suggest that MR1 can accommodate a range of different ligands
because of plasticity in ligand orientation of the binding
cavity4,18–22. As the pterin ring occurs commonly in the
environment, it is feasible that other microbial or host
molecules with common chemotypic properties could bind to
MR1, and function as antigens for MR1-restricted T cells. We
hypothesize that diversity in MR1 ligands allows MR1-restricted
T cells to recognize a wide range of microorganisms and their
associated metabolomes.
In contrast to conventional T-cell populations, MAIT cells can
be found in the thymus with effector pathogen-reactive
capability13 and their selection depends on haematopoietic
rather than epithelial cells12,38,47. It is unknown whether innate
T-cell function is a T-cell-intrinsic programme or is a result of
TCR signalling through selection in the thymus by MR1. Both
functional data and tetramer staining demonstrate the presence of
MR1-restricted T cells in all donors. Because we do not have a
TRAV12-2 antibody, the full TCR repertoire of these cells
remains to be determined as well as whether they share the innate
T-cell attributes and selection pathway of TRAV1-2þ MR1-
restricted T cells.
We also note the preponderance of MR1-restricted T cells
expressing the TRAV1-2 TCR, in line with prior observations10.
This phenomenon could occur by a scenario where TRAV1-2þ
T-cell selection in the thymus is favoured over other TCRs.
Alternatively, given evidence of ligand discrimination by MAIT
TCRs, TRAV1-2þ MAIT cells could dominate in the periphery
because of selective microbial exposures. In line with this
hypothesis, perhaps repeated exposures of environmental
mycobacteria or Gram-negative gut microbiota allow for
preferential expansion of TRAV1-2þ MR1-restricted T cells in
the majority of individuals.
On the basis of our ﬁndings, we propose that non-TRAV1-2
MR1-restricted TCRs contribute to immune defence against
infection primarily by providing more diverse and, in some
instances, unique microbial recognition. For instance, the
TRAV12-2þ MR1-restricted T-cell clone can recognize infection
with S. pyogenes. A variety of diseases are caused by infection by
S. pyogenes or Group A streptococcus48. These include throat
infection ‘strep throat’, pneumonia, fasciitis, nosocomial wound
infection and glomerulonephritis. We hypothesize that MR1-
restricted T cells expressing TRAV12-2þ or other atypical TCRs
selectively expand at tissue sites, such as the human mouth,
tonsils and skin, associated with streptococcal infection. Our prior
ﬁnding of microbe-selective clonal MR1-restricted T-cell
expansions within individuals23, in conjunction with the data
presented herein, demonstrates the capacity of MR1-restricted T
cells to discriminate between microbial infections, and supports
the hypothesis that MAIT cells display antigen-driven clonal
expansion.
In sum, we show that MR1-restricted T cells have the capacity to
detect a greater diversity of microbes than previously shown.
We have isolated a human T-cell clone that expresses a TCR never
observed within MAIT cells before, TRAV12-2, demonstrating
that MR1-restricted T cells do not use TRAV1-2 exclusively.
This TRAV12-2 TCR displays MR1-Ag discrimination both with
regard to the recognition of known RL metabolites, and most
notably in its capacity to uniquely detect S. pyogenes, a pathogen
that lacks the capacity to synthesize riboﬂavin. Collectively, these
data provide evidence that additional MAIT cell subsets may play
a unique role in human defence against infection by broadening
the recognition of microbes and their associated metabolites.
Methods
Human participants. All samples were collected and all experiments were con-
ducted under protocols approved by the institutional review board at Oregon
Health and Science University. PBMCs were obtained by apheresis from healthy
adult donors with informed consent.
Cell lines and reagents. All cell lines used in this study have been conﬁrmed to be
mycoplasma-free. The A549 lung carcinoma cell line (ATCC CCL-185) was used as
APCs for IFN-g ELISPOT assays in Figs 1 and 2, direct ex vivo intracellular
cytokine staining determination of microbe-reactive T cells and in Fig. 4c for
infection with Neisseria gonorrhoeae and Y. enterolitica. The BEAS2B bronchial
epithelial cell line was used (ATCC CRL-9609) in Fig. 3 for antibody blockade
ELISPOT assays. Cell lines were maintained by continuous passage in F12K culture
medium supplemented with 10% fetal bovine serum. RL-6,7-diMe and RL-6-Me-7-
OH were purchased from WuXi Apptec and 6FP from Schick Laboratories. Live-
dead aqua stain and carboxyﬂuorescein succinimidyl ester (CFSE) were purchased
from Life Technologies. Unconjugated antibodies used in the study were the fol-
lowing: anti (a)-CD3 (clone OKT3), abTCR (clone T10B9, BD), aMR1 (26.5, gift
from Ted Hansen), aHLA-ABC (W6-32, AbD Serotec), aCD1a/CD1b/CD1c/CD1d
(gift from Branch Moody), aIFNg for ELISPOT (Mabtech, see ELISPOT methods
section below) and LEAF puriﬁed IgG2a, IgG1 and IgM isotype controls (Biole-
gend). Conjugated antibodies used in this study were the following: aCD3
(UCHT1, ﬂuorescein isothiocyanate (FITC) or PerCP Cy5.5, 1:50 dilution, Biole-
gend, BL), aTRBV29-1 FITC (1:10 dilution, Beckman Coulter), aCD8a (APC-Cy7,
1:500 dilution, clone RPA-T8, BL), aCD26 (FITC, 1:50 dilution, clone BA5b, BL),
aCD161 (PE-Cy7, 1:50 dilution, HP-3G10, BL), aCD4 (Brilliant violet 785, 1:50
dilution, OKT4, BL), aIFNg FITC (1:25 dilution, Beckman Coulter), abTCR
(phycoerythrin (PE), 1:50 dilution, clone T10B9, BD) and IgG2a isotype conjugated
to FITC (BD), aTRAV1-2 (APC, 1:50 dilution, OF5A12)13, aCD247 pY142 (PE,
1:10 dilution, BD Phosﬂow), aZAP-70 pY319/Syk pY352 (PE, 1:10 dilution, BD
Phosﬂow) and aTCRgd (FITC, 1:25 dilution, clone B1, BD). 5-OP-RU: 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil.
Monocyte-derived DCs. PBMCs obtained by apheresis were resuspended in 2%
human serum (HS) in RPMI and were allowed to adhere to a T-75 ﬂask at 37 C for
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1 h. After gentle washing twice with PBS, nonadherent cells were removed and 10%
HS in RPMI containing 30 ngml 1 of IL-4 (Immunex) and 30 ngml 1 of
granulocyte–macrophage colony-stimulating factor (Immunex) was added to the
adherent cells. The cells were X-rayed with 3,000 cGray using X-RAD320 (Preci-
sion X-Ray Inc.) to prevent cell division. After 5 days, cells were harvested with
cell-dissociation medium (Sigma-Aldrich, Gillingham, UK) and used as APCs in
assays.
Generation of an MR1-knockout cell line using CRISPR/Cas9. The reagents
used to mutate the MR1 gene were derived from the toolkit described in ref. 49. A
codon-optimized synthetic Cas9 cDNA under the control of the cytomegalovirus
promoter (Addgene plasmid #41815) was used in combination with a single guide
RNA comprising a transactivating CRISPR RNA sequence49 as well as the 19-
nucleotide protospacer sequence (50-GATGGGATCCGAAACGCCC-30) targeting
the þ strand of exon 3 of the MR1 gene followed by the protospacer-associated
motif AGG. Plasmid DNA serving as template for the transcription of the CRISPR/
Cas9 elements was transfected in the carcinomic human alveolar basal epithelial
cell line A549 using Lipofectamine 2000 (Invitrogen, Life Technologies, Paisley,
UK) according to the manufacturer’s instructions. Genomic DNA from A549 cells
was isolated with the GenELute mammalian genomic DNA miniprep kit (Sigma-
Aldrich). Mutations at the target site were detected using the CEL-I enzyme, as part
of the SURVEYOR assay (Transgenomic Ltd, Glasgow, UK), which cleaves DNA
duplexes bearing base pair mismatches, caused by insertions or deletions at
proximity of the protospacer-associated motif sequence, within the PCR amplicons
generated with primers ﬂanking the genomic target site. The PCR forward primer
(50-GCATGTGTTTGTGTGCCTGT-30) is located in the intron region upstream of
the target site and the reverse primer (50-GGTGCAATTCAGCATCCGC-30)
downstream on exon 3. MR1 protein expression at the cell surface was measured
using ﬂow cytometry with the anti-MR1 antibody clone 26.5 (a kind gift from
Professor Ted Hansen) following overnight stabilization by incubating cells with
50mgml 1 acetyl-6-formylpterin (Schirks Laboratories, Jona, Switzerland). MR1-
negative cells were sorted using ﬂow cytometry and single-cell clones were derived
from the sorted bulk population by limiting dilution (average of 0.3 cells per well).
Clonal populations were then screened for MR1 surface expression and DNA
indels with the SURVEYOR assay. The region ﬂanking the target site was PCR-
ampliﬁed from the genomic DNA of selected clones using the primers described
above fused to restriction sites and the PCR products were cloned into recipient
plasmids, which were transfected in chemically competent Top10 E. coli bacteria.
Ten colonies that tested positive for the insert by colony PCR were used to produce
plasmid Minipreps, which were sent for Sanger sequencing in order to determine
the nature of CRISPR/Cas9-induced mutations. Clone 9 (in the manuscript as
MR1 / ) was shown to bear a 125 bp deletion on one allele and a single bp
deletion on the other.
Isolation of TRAV1-2-negative T-cell lines and clones. CD8þ , CD4 , gd
TCR and TRAV1-2-negative T cells were FACS-sorted from PBMCs, and
1 106 were added to 1 105 irradiated (3,500 rad using a Cs source) monocyte-
derived autologous DCs infected with M. smegmatis (MOI 3) and incubated in
RPMI 1640 with 10% HS, rhIL-2 (2 ngml 1) and rhIL-12 (0.5 ngml 1). Seven
days later, T cells were removed and stained with CFSE, and then added to 1 105
irradiated (3,500 rad) monocyte-derived autologous macrophages infected with
M. smegmatis (MOI 3) and incubated with rhIL-2 (2 ngml 1) for another week.
The resulting T-cell line was FACS-sorted for CFSE-diluted cells. The sorted T cells
were rested overnight in RPMI 1640 supplemented with 10% HS and 0.5 ngml 1
rhIL-2. The CFSE-sorted T-cell line was rapidly expanded using anti-CD3 fol-
lowing the protocol written below, then FACS-puriﬁed based on its ability to bind
MR1 tetramer loaded with 5-OP-RU (ref. 4), rested overnight with rhIL-2
(0.5 ngml 1) and rapidly expanded using anti-CD3 again to generate ‘D462-E4’
T-cell clone.
Expansion of T-cell clones. T-cell clones were cultured in the presence of X-rayed
(3,000 cGray using X-RAD320, Precision X-Ray Inc.) allogeneic PBMCs, X-rayed
allogeneic LCL (6,000 cGray) and anti-CD3 monoclonal antibody (20 ngml 1;
Orthoclone OKT3, eBioscience) in RPMI 1640 media with 10% HS in a T-25
upright ﬂask in a total volume of 30ml. The cultures were supplemented with IL-2
on days 1, 4, 7 and 10 of culture. The cell cultures were washed on day 5 to remove
soluble anti-CD3 monoclonal antibody.
Phosphorylation-speciﬁc T-cell staining for ﬂow cytometry. T-cell clones were
incubated overnight in RPMI media containing 0.5 ngml 1 IL-2 and 2% HS.
Monocyte-derived DCs were incubated for one hour with S. pyogenes orM. smegmatis
MOI¼ 10, or nothing, in ultra low adherence culture plates. A three to one ratio of
DCs to T cells was co-incubated for 15min at 37 C and then immediately ﬁxed in
2% paraformaldehyde. Following ﬁxation, the cells were permeabilized in ice-cold
100% methanol for 30min. Then, the cells were washed in FACS buffer to sufﬁciently
remove the methanol and stained with the following antibodies: anti-CD8
(clone RPA-T8, 1:50 dilution, Biolegend), anti-CD3z-pY142 (1:10 dilution, BD),
anti-ZAP-70 pY319/Syk pY352 (1:10 dilution BD) or isotype controls (IgG2a for
anti-CD3z, IgG1 for anti-ZAP-70, used at a matching concentration to their
orresponding phospho-speciﬁc antibody) for 45min at 4 C. Isotype controls were
used to optimize staining with phospho-speciﬁc antibodies. We use the mitogen PHA
as a positive control for TCR stimulation and maximum phosphorylation signal. A
minimum of 30,000 CD8þ events were collected for geometric mean ﬂuorescence
intensity analysis across samples.
Analysis of TCR usage. Ampliﬁcation and sequencing of TCRB and TCRAD
CDR3 regions were performed using the immunoSEQ Platform (Adaptive Bio-
technologies, Seattle, WA). ImmunoSEQ combines multiplex PCR with high-
throughput sequencing and a bioinformatics pipeline for (TCRB/TCRAD) CDR3
region analysis50,51. The IMTG nomenclature was used throughout the study52.
Flow cytometry staining and cell sorting. Cells to be analysed for cell surface
marker expression were ﬁrst incubated at 4 C in a blocking solution of PBS
containing 2% normal rabbit serum (Sigma-Aldrich), 2% normal goat serum
(Sigma-Aldrich) and 2% HS to prevent nonspeciﬁc binding. Cells were washed in
PBS and then incubated with live-dead discriminator and surface stains or isotype
controls for 20min in the dark at 4 C in a total volume of 50ml. Cells were then
washed and ﬁxed, or ﬁxed and permeabilized (ex vivo ICS tests, BD Fix/Perm kit)
according to the manufacturer’s instructions. Antibodies for intracellular staining
were then added for 30min in the dark at 4 C in a total volume of 50ml, and after
washing ﬂow cytometry was performed. Speciﬁcally for Fig. 3a, 2 106 PBMCs from
each donor were stained with the MR1-Ag tetramer at 0.3 nM in 25ml volume for
45min in PBS buffer containing 2% fetal bovine serum at room temperature in the
dark. Viability and surface stains were added on top of the tetramer stain for another
20min at 4 C. Samples were then washed twice in tetramer staining buffer. All ﬂow
cytometry analyses were performed on a Fortessa 18-parameter ﬂow cytometer (BD).
All FACS analyses were performed using an Inﬂux 11-parameter ﬂow cytometer
(BD) with the Oregon Health and Science University ﬂow cytometry core facility.
Data were analysed using FlowJo (v9.8.5). Fluorescence minus one controls were
used for optimal gating. Doublets were excluded based on FSC-H and FSC-A, SSC-H
and SSC-A; lymphocytes were identiﬁed based on FSC-A and SSC-A and CD3
expression; and dead cells were excluded based on Aqua viability dye.
Ex vivo stimulation assay. To observe the nonclassical T-cell response, we used
the A549 cell line as APCs because it does not express MHC-II and is MHC-I-
mismatched to the donor source of T cells. CD8þ T cells were positively selected
from healthy donor PBMCs using magnetic bead separation according to the
manufacturer’s instructions (Miltenyi), added to uninfected WT or M. smegmatis-
infected (MOI¼ 3, overnight infection) WT or MR1 / A549 cells at a ratio of
3:1 and incubated overnight in the presence of Brefeldin A and 0.5 ngml 1 rhIL-2
at 37 C. The following day, the cells were stained for surface phenotype markers
and live-dead discriminator. Following surface staining, cells were ﬁxed and per-
meabilized using the BD Fix/Perm Kit and stained intracellularly with a-IFN-g.
Microorganisms and preparation of APCs. M. smegmatis, C. albicans, S. enterica
Typhimurium, E. coli, M. tuberculosis, S. pyogenes and M. avium were used from
frozen glycerol stocks, whereas all other microbes were harvested from overnight
growth on agar plates and titred based on OD600 readings of a colony suspension.
A cell-free supernatant was created from an overnight culture of S. pyogenes
(ATCC 19615) that was sterile-ﬁltered and frozen before being used in T-cell
stimulation assays of Fig. 5c–f. A549 cells were infected for 2 h or DCs were
infected for 1 h with microbes at 37 C. In ﬁg. 4c, A549 cells were used for Yersinia
and Shigella infections; DCs were used for all other infections. The MOI and
antibiotics used for each microbe were optimized for APC viability and maximal
MR1-restricted response: E. coli 1, M. smegmatis 3, S. ﬂexneri 1, Y. enterolitica 1, C.
albicans 0.1, M. avium 30, N. asteroides 1, S. enterica Typhimurium 30, V. para-
hemolitica 1, M. tuberculosis 30, N. gonorrhoeae 1, P. aeruginosa 1, S. aureus 1, S.
pyogenes 30, E. faecalis 1 and 10. All infections were performed in the absence of
antibiotics. After the indicated infection time, all cells were washed twice in media
containing antibiotics and then incubated overnight in an ultra low adherence
tissue culture plate before being counted and added to the assay (ELISPOT set-up
described below).
Riboﬂavin dependence growth assay. Overall, 5 106 colony-forming unit from
frozen glycerol stocks of S. pyogenes or E. coli were added to 10ml of minimal
growth media and cultured at 37 C for 96 h (S. pyogenes) or 12 h (E. coli) in the
dark. Minimal growth media was made with M9 salts (BD Difco) supplemented
with glucose, MgSO4 and CaCl2, as recommended by the manufacturer, and 0.01%
w/v amino acids (casein enzymatic digest, Sigma). Riboﬂavin (Sigma) was added to
the growth medium at mM concentrations indicated in Fig. 5. Bacterial growth was
measured by absorbance readings at 600 nm.
IFN-c ELISPOT assay and antibody blocking. A MSHA S4510 96-well nitro-
cellulose-backed plates (Millipore, bought via Fisher Scientiﬁc) was coated over-
night at 4 C with 10mgml 1 solution of anti-IFN-g monoclonal antibody
(Mabtech clone 1-D1K) in a buffer solution of 0.1M Na2CO3, 0.1M NaHCO3,
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pH¼ 9.6). Then, the plate was washed three times with sterile PBS and blocked for
1 h at room temperature with RPMI 1640 media containing 10% heat-inactivated
HS pool. Then, the APCs and T cells were prepared as described below and co-
incubated overnight. Brieﬂy, DCs (Figs 4a,d and 5), the BEAS2B cell line (Fig. 3d)
or the A549 cell line (all other experiments) were used as APCs at 1 104 per well
in ELISPOT assays. For all blocking ELISPOT assays, APCs were limited to 5 103
per well. In Fig. 4b,c, the A549 cell line was incubated with MAIT antigens over a
range of concentrations in the dark for 2 h. Where stated, blocking antibodies or
antagonists were added for 2 h at 2.5 mgml 1 (a-HLA-I clone W6/32, a-CD1a, b,
c, d (Branch Moody), 6-formyl pterin (50 mgml 1, Schick Laboratories) and a-
MR1 clone 26.5 (Ted Hansen) or appropriate isotype controls). To block the T-cell
receptor, anti-abTCR (clone T10B9 (ref. 53), BD Pharmingen) or isotype control
was added to T-cell clones at 0.5 mgml 1 for 30min at 4 C before co-incubation
with APCs, T-cell clones were added at 1 104 per well. The plate was incubated
overnight at 37 C and then washed six times with PBS containing 0.05% Tween.
The plate was then incubated for 2 h at room temperature with a 1 mgml 1
solution of anti-IFN-g-biotin secondary antibody (Mabtech clone 7-B6-1) in 0.5%
BSA, 0.05% Tween in PBS. Finally, the plate was washed six times in PBS-Tween,
and then PBS, and developed using an AEC Vectastain kit SK-4200 (Vector labs).
We deﬁned a positive response as greater than 25 IFN-g spot-forming units.
Preparation of pulsed ﬁxed APC. Monocyte-derived DCs were pulsed for 4 h
with bacterial culture supernatant from S. pyogenes or left untreated and then
washed and rested overnight in an ultra low adherence tissue culture plate. The
following day, the pulsed DC-conditioned media (Fig. 5c) was collected and added
to the D462-E4 clone in the ELISPOT plate. Then, half of each harvested DC
sample was used in the ELISPOT as ‘unﬁxed’. The other half was ﬁxed by incu-
bating in 0.5% paraformaldehyde (Electron Microscopy Sciences) in PBS for
15min at room temperature. Then, an equal volume of 0.4M lysine was added to
stop the reaction for 5min. The samples were then extensively washed with media,
incubated for 1 h at 37 C and then washed again before being used in the ELISPOT
assay.
Data Analysis. Flow cytometry data were analysed using FlowJo software 9.8.1
(Tree Star). All statistical analyses were performed using the Prism software with
nonparametric, the Mann–Whitney U-tests (Fig. 2c). Nonparametric statistical
tests were used for small group sizes (ﬁve donors in this study). In all descriptive
statistical analyses, the variance was ﬁrst conﬁrmed to be similar between groups
using s.d. or s.e.m. tests, as appropriate and displayed on each graph. P
valuesr0.05 were considered signiﬁcant (*Pr0.05).
Data Availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files, or
are available from the corresponding author upon request.
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